Advertisement
About Maven Biotechnologies
Maven Biotechnologies, LLC has developed LFIRE(TM) (Label-Free InternalReflection Ellipsometry) which is a complete diagnostics analysis system(instruments and disposables) that provides a next generation replacementmeasurement technology with significant cost benefits to the healthcare sectorand technology improvements for the combined $15 B w/w immunodiagnosticmarkets. It offers the potential advantages of 50-75% reduced costs to boththe diagnostics manufacturers and the clinical or pharma lab user. Inaddition, its breakthrough new way to measure immunodiagnostic tests morerapidly will positively impact point-of-care (POC) tests for emergency roomscreening (e.g. cardiac markers, drugs of abuse, etc.), at patient bedside,and in the O.R. Finally, it uniquely permits single to high densitylabel-free multiplexing -- that is, when one to large numbers of tests perpatient can be run at one time (e.g. tumor markers, autoimmune panels, etc.),greatly reducing costs for the patients, healthcare provider and importantly,the medical insurance industry. LFIRE(TM) is an enabling technology for morecost effective patient profiling of multiple tests for diagnosis, staging ofdisease and choice of targeted drug therapy, all key elements required for themedical industry's personalized medicine initiative. Most significantly, themarket infrastructure for this technology already exists in the worldwidediagnostics and pharma industries and market penetration for this improvednext generation, markedly cost effective, replacement measurement technologywill be rapid. The Company is now planning development for the firstcommercial versions of LFIRE(TM), with planned market launch later in 2008.
http://www.mavenbiotech.com
SOURCE Maven Biotechnologies, LLC
